PT  - JOURNAL ARTICLE
AU  - Janne Hukkanen
AU  - Pleyton Jacob III
AU  - Neal L. Benowitz
TI  - Metabolism and Disposition Kinetics of Nicotine
AID  - 10.1124/pr.57.1.3
DP  - 2005 Mar 01
TA  - Pharmacological Reviews
PG  - 79--115
VI  - 57
IP  - 1
4099  - http://pharmrev.aspetjournals.org/content/57/1/79.short
4100  - http://pharmrev.aspetjournals.org/content/57/1/79.full
SO  - Pharmacol Rev2005 Mar 01; 57
AB  - Nicotine is of importance as the addictive chemical in tobacco, pharmacotherapy for smoking cessation, a potential medication for several diseases, and a useful probe drug for phenotyping cytochrome P450 2A6 (CYP2A6). We review current knowledge about the metabolism and disposition kinetics of nicotine, some other naturally occurring tobacco alkaloids, and nicotine analogs that are under development as potential therapeutic agents. The focus is on studies in humans, but animal data are mentioned when relevant to the interpretation of human data. The pathways of nicotine metabolism are described in detail. Absorption, distribution, metabolism, and excretion of nicotine and related compounds are reviewed. Enzymes involved in nicotine metabolism including cytochrome P450 enzymes, aldehyde oxidase, flavin-containing monooxygenase 3, amine N-methyltransferase, and UDP-glucuronosyltransferases are represented, as well as factors affecting metabolism, such as genetic variations in metabolic enzymes, effects of diet, age, gender, pregnancy, liver and kidney diseases, and racial and ethnic differences. Also effects of smoking and various inhibitors and inducers, including oral contraceptives, on nicotine metabolism are discussed. Due to the significance of the CYP2A6 enzyme in nicotine clearance, special emphasis is given to the effects and population distributions of CYP2A6 alleles and the regulation of CYP2A6 enzyme.